Key facts about ISO 14971,

ISO 14971 is the essential standard for risk management in medical devices. As technology advances in areas like AI and device innovation, ensuring patient safety and regulatory compliance has never been more critical. ISO 14971:2019 offers a comprehensive framework for identifying, assessing, and controlling risks, making it indispensable for organisations in the medical device industry. Here, we answer frequently asked questions about ISO 14971, its importance, and its practical relevance to your business.

Learn about our ISO Services

ISO 14971 is a globally recognised standard for risk management specific to medical devices. The standard outlines a comprehensive process that helps manufacturers identify, assess, manage, and monitor risks associated with medical devices throughout their lifecycle.
The goal is to ensure that devices are safe for their intended use and meet regulatory requirements across different markets like the EU and the USA. The standard applies to both hardware and software devices, including in vitro diagnostics. It emphasises a proactive approach where risk management starts early in the design phase and continues throughout the entire evolution of the device, including into the post-market phase.

ISO 14971 is an essential standard for medical device companies, rather than an optional one, for several key reasons. Firstly, regulatory compliance is a major factor. As an international standard, ISO 14971 is required by many regulatory regimes, such as the EU Medical Device Regulations (MDR) and the US Food and Drug Administration (FDA), as part of the medical device approval process, underscoring the importance of the standard for gaining market access. 

Additionally, ISO 14971  plays a critical role in patient safety. By following a structured risk management process as outlined in ISO 14971, companies can better anticipate and mitigate potential hazards, helping to ensure patient safety. 

Beyond compliance and safety, adhering to ISO 14971 also builds reputation and trust. ISO 14971 helps companies establish credibility and trust among healthcare providers, patients and regulatory bodies. It provides the right signals that the company is committed to high-quality standards and patient welfare. 

Finally, the standard promotes continuous improvement, encouraging companies to regularly monitor and improve their devices based on real-world data, ensuring that safety and performance evolve alongside clinical needs.  

The standard establishes a systematic process for managing risks throughout the medical device lifecycle, including:

Risk Management Plan

A risk management plan is the cornerstone of ISO 14971 compliance. It is designed to provide a structured approach to identifying and mitigating risks associated with a medical device. The plan needs to outline the scope of risk, the responsibilities of specific team members, and methods for risk management activities. 

Risk Analysis

The risk analysis focuses on identifying potential hazards associated with the device and estimating the severity and probability of each risk.  This involves a systematic examination of how the device could fail and the consequences of such failures.

Risk Evaluation

This involves assessing identified risks against predefined acceptability criteria to determine whether risks can be accepted or need mitigation. These criteria is based on regulatory requirements, industry standards and organisational policies.

Risk Control

In the risk control phase, measures are implemented to eliminate or mitigate risks to acceptable levels. This will include design modifications such as engineering changes to eliminate a hazard, protective measures such as warnings, and safety information to minimise user-related risks. You are also required to verify that the risk control measures you have selected are effective in mitigating risk.

Evaluation of Overall Residual Risk

After implementing the risk control measures the organisation now needs to evaluate the overall residual risk to determine if the remaining risks are acceptable. This will include reviewing the effectiveness of the control measures and if the remaining risks are within acceptable levels. Within this step, a benefit-risk analysis also needs to be conducted to consider the overall benefit of the device compared to the overall residual risk. Regulatory authorities often require this analysis to ensure that the device’s therapeutic benefits outweigh the potential harms.

Risk Management Review

The risk management review process ensures the risk management plan remains relevant and effective over time, incorporating new information and changes. 

By including these components, medical device manufacturers can establish a comprehensive risk management system that aligns with ISO 14971:2019 requirements and helps ensure the safety and effectiveness of their products.

To ensure compliance with ISO 14971, certain stakeholders within the business need to be familiar with the standard and hold specific roles to ensure this: 

Top Management: 

Top Management should have a strong understanding of ISO 14971 as they are responsible for establishing the risk management policy and risk acceptability criteria. They also need to ensure they are providing adequate resources for risk management activities and approve the risk management plan and the effectiveness of the risk management process. 

Quality Assurance/Regulatory Affairs: 

Quality Assurance or Regulatory Affairs play a crucial role in the implementation of ISO 14971. They will be responsible for developing and maintaining the risk management system, ensuring compliance with regulatory requirements and conducting internal audits of the risk management process. 

Manufacturing: 

Manufacturing will be implementing risk control measures during the production processes, monitoring production for potential new risks and managing supplier-related risks.

Software Development:

Software development teams will help identify, assess, and mitigate software-related risks, especially those that could impact patient safety or device performance.

Clinical Affairs: 

Clinical Affairs needs to assess the clinical risks associated with the description, design clinical trials to evaluate the device’s safety and conduct post-market clinical follow-up.

ISO 14971 is widely recognised by regulatory authorities in major markets, including the US FDA, EU MDR, UK MHRA, and Health Canada, as the primary standard for risk management in the medical device industry. Compliance with ISO 14971 is essential for manufacturers aiming to meet regulatory requirements, as it provides a structured approach to identifying, evaluating, and mitigating risks associated with medical devices.

With the release of ISO 14971:2019 and the amendment EN ISO 14971:2019+A11:2021, risk management practices have been further aligned with the EU’s MDR and the In Vitro Diagnostic Regulation (IVDR), ensuring ISO 14971’s relevance to both medical devices and in vitro diagnostics in the EU. This harmonisation ensures that manufacturers have a consistent and regulatory-compliant approach to risk management across these product categories.

ISO 14971 also aligns closely with other international standards and quality management systems crucial for regulatory compliance, such as IEC 62304 for medical device software and ISO 13485 for quality management systems. IEC 62304 specifically integrates risk management into software development by requiring manufacturers to evaluate software-related risks and their potential to contribute to hazardous situations. Similarly, ISO 13485 emphasises risk management throughout the product lifecycle, mirroring ISO 14971’s principles and reinforcing a consistent, risk-focused approach.

All three standards—ISO 14971, IEC 62304, and ISO 13485—stress the importance of detailed documentation and traceability, creating a cohesive framework for managing safety, quality, and effectiveness in medical device development. By following this integrated approach, manufacturers can meet stringent regulatory demands while delivering safe, high-quality products to the market.

The synergy among these standards establishes a baseline framework for software medical device developers, ensuring that risk management, software development, and quality assurance are embedded throughout the entire product lifecycle.

ISO 14971 can provide several key benefits to medical device organisations beyond just regulatory compliance:

Improved Product Safety and Quality

Organisations can systematically identify potential hazards and risks early in the development process, allowing them to improve product safety from the beginning of its lifecycle. They can also ensure that they evaluate and prioritise risk based on severity and probability, helping to improve overall product safety and quality by addressing potential issues proactively rather than reactively.

Enhanced Decision Making

ISO 14971 provides a framework for conducting benefit-risk analyses for medical devices, which is crucial given the potential impact of these devices on patient safety. This dual focus on both risk and benefit allows manufacturers to assess whether the therapeutic benefits justify the inherent risks, taking into account both device performance and patient outcomes. By framing risk within the context of benefit, ISO 14971 enables a more balanced and nuanced decision-making process, where the acceptable level of risk can be directly aligned with expected clinical benefits.

Lifecycle Risk Management

ISO 14971 emphasises the importance of implementing risk management during the entire product lifecycle, as mentioned before. This means that from the initial concept and design phase to post-market surveillance. Therefore, the approach allows organisations to continuously monitor, assess and control risk. 

Improved Efficiency

Implementing international standards often seems like a headache as well as a drain on resources and time. However, despite ISO 14971 requiring upfront investment, it can lead to long-term gains. The standard will allow you to identify and address issues earlier when they could be less costly as well as reduce the likelihood of product recalls and field actions. ISO 14971 also allows organisations to streamline their regulatory submissions by providing well-documented risk management processes, saving time down the line. 

Enhanced Organisational Risk Culture

Adopting ISO 14971 can help foster a risk-based mindset throughout the organisation by encouraging cross-functional collaboration on risk management activities. This cultural shift can lead to improved product quality and safety across an organisation’s entire portfolio.

Integration with DCB0129 for access to the NHS

ISO 14971 integrates effectively with DCB0129, the NHS clinical risk management standard for Health IT systems, offering significant advantages for medical device companies. By following ISO 14971, these companies can systematically identify and mitigate risks associated with their products, thereby aiding compliance with the stringent safety standards set by the NHS. Incorporating the requirements of DCB0129 during the ISO 14971 process streamlines the evaluation and approval workflow with NHS bodies. Consequently, adhering to both standards not only expedites access to NHS resources but also enhances the delivery of safer and more effective medical devices to patients.

By fully embracing the principles of ISO 14971 beyond just checking compliance boxes, medical device companies can realise significant benefits in terms of product quality, organisational efficiency, and long-term risk reduction.

Medical Devices containing AI components can apply ISO 14971, but there is little guidance within it for the risks related to Artificial Intelligence systems. Thankfully, the British Standards Institute and the Association for the Advancement of Medical Instrumentation have developed BS/AAMI 34971, which contains specific guidance to AI medical device companies on how to manage risks associated with medical devices within the framework of ISO 14971.

BS/AAMI 34971 is currently being reviewed and considered for adoption as an International Standard as PD ISO/TS 24971-2 (although this is not expected to happen until early 2026).

Conclusion

In today’s dynamic medical technology landscape, ISO 14971 has emerged as a strategic imperative for effective risk management in the medical device industry. Far beyond a regulatory checkbox, this standard provides a robust framework that empowers organisations to proactively identify, assess, and mitigate risks throughout the product lifecycle. By adopting ISO 14971, companies foster a culture centred on safety, quality, and continuous improvement, ensuring that devices are not only compliant but also optimised for patient safety.

With rapid advancements in medical technology, ISO 14971’s relevance continues to grow, reinforcing trust among healthcare providers, patients, and regulatory bodies. Integrating this standard into operational processes enhances decision-making, boosts efficiency, and ultimately strengthens product reliability. ISO 14971, therefore, is more than a compliance requirement; it’s a critical investment in patient safety and organisational excellence, positioning companies for success in an evolving industry.

We’re the experts that have your back.

Let us help you find a route from from where you are, to where you need to go. We’re here to help.

Book a Call with our Expert Team

Other Articles​

Loading...